InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Featured in Research Report
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, was featured in a research report by the Benchmark Company LLC. The report, titled “Processa Pharmaceuticals Inc. (PCSA) Processing Assets to the FDA; Initiate at Buy,” lists a $15 price target at initiation of coverage. The report reads, “We initiate…